The procalcitonin test is relatively new, but its utilization is increasing. Recent studies have shown that it has promise in helping to evaluate the risk that a seriously ill person is developing a systemicbacterial infection. It has primarily been studied in people who present to Emergency Departments or who are admitted to intensive care units (ICUs) and who have symptoms that may be due to sepsis. The procalcitonin test has been approved by the U.S. Food and Drug Administration (FDA) for use in conjunction with other laboratory findings and clinical assessments to assist in the risk assessment of critically ill people for progression to severe sepsis and septic shock. For diagnostic purposes, it is best used during the first day of presentation. It may be used later on to monitor the response to treatment.
It may sometimes be ordered when a person has tissue damage due to events such as trauma or surgery or a viral illness such as pneumonia in order to detect the development of a secondary bacterial infection.
Occasionally, a procalcitonin test may be ordered at intervals to monitor the effectiveness of antimicrobial treatment.
The procalcitonin test may be ordered along with other tests when a seriously ill person has symptoms that suggest that the person may have a systemic or severe bacterial infection. When used, it is typically ordered as an early detection tool, within the first day of hospital admission.
More severe symptoms include inflammation throughout the body and formation of many tiny blood clots in the smallest blood vessels. One or more organs may begin to stop working (multi-organ failure, MOF) and there may be a dangerous drop in blood pressure.
Sometimes, procalcitonin may be ordered at intervals to monitor antimicrobial therapy in persons suspected of having sepsis. It may occasionally be ordered when someone has tissue damage from trauma, surgery, or a burn, or a viral illness such a pneumonia and a health practitioner suspects that the person may have developed a secondary infection.
Low levels of procalcitonin in a seriously ill person represent a low risk of sepsis and progression to severe sepsis and/or septic shock but do not exclude it. Low concentrations may indicate a localized infection that has not yet become systemic or a systemic infection that is less than six hours old. It may also indicate that the person's symptoms are likely due to another cause, such as transplant rejection, a viral infection, or trauma – post-surgery or otherwise.
High levels indicate a high probability of sepsis, that is, a higher likelihood of a bacterial cause for the symptoms. They also suggest a higher risk of progression to severe sepsis and then to septic shock.
Moderate elevations may be due to a non-infectious condition or due to an early infection and, along with other findings, should be reviewed carefully. Decreasing procalcitonin levels in a person being treated for a severe bacterial infection indicate a response to therapy.
Very high levels of procalcitonin can be seen with medullary thyroid cancer, but the test is not used to diagnose or monitor this condition.
The procalcitonin test is not considered a replacement for the performance of other laboratory tests. Rather, it provides additional information that may allow appropriate treatment to be initiated sooner.
Early detection of systemicbacterial infections, including bacterial pneumonia and bacterial meningitis, is important because they can be life-threatening and can be readily treated. However, the inappropriate use of antibiotics in cases where the illness is not bacterial in origin may cause delays in proper treatment and can encourage the development of antibiotic-resistant organisms.
The procalcitonin test is being studied in additional populations, expanding beyond critically ill ICU patients. As more data are gathered, its clinical usefulness will be better understood and its intended use(s) more fully defined.
This article was last reviewed on August 21, 2013. | This article was last modified on February 24, 2015.
The review date indicates when the article was last reviewed from beginning to end to ensure that it reflects the most current science. A review may not require any modifications to the article, so the two dates may not always agree.
The modified date indicates that one or more changes were made to the article. Such changes may or may not result from a full review of the article, so the two dates may not always agree.